Fátima T. M.
- Country
- Spain
- Department
- Oncology
Research Overview
- A Pharmacokinetic Comparison of JPB898 and Nivolumab in Patients with Resected Stage IIB, IIC, or III Melanoma in the Adjuvant Setting
- Pharmacokinetic, Safety, and Immunogenicity Comparison of Bmab1700 Versus Nivolumab as Adjuvant Monotherapy in Stage IIB–C, III, and IV Melanoma
- Efficacy and Safety Evaluation of Enfortumab Vedotin and Pembrolizumab in Advanced Melanoma: A Phase II, Open-Label, Multicenter Study
Data & Insights
Has run more than one trial at 12 of 47 partner sites.
Specializations
Oncologic Therapeutics: Breast Cancer
Focus on hormone receptor‑positive and HER2‑negative disease subtypes across early and advanced stages.
- Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer
- HR+ HER2‑negative metastatic breast cancer
- Triple‑negative breast cancer with CNS involvement
- HER2‑low breast cancer in post‑neoadjuvant settings
Research integrates endocrine therapy, CDK4/6 inhibition and novel antibody‑drug conjugates.
Oncologic Therapeutics: Lung Cancer
Investigation of targeted strategies for non‑small cell lung carcinoma subtypes, including driver‑mutated disease.
- ALK fusion‑positive NSCLC
- EGFR‑mutated NSCLC
- KRAS G12C‑mutant NSCLC
- Advanced squamous NSCLC
Efforts emphasize precision medicine and immunotherapy combinations.
Hematologic Malignancies
Clinical focus on acute myeloid leukemia and related myelodysplastic syndromes.
- Acute Myeloid Leukemia with measurable residual disease
- High‑risk myelodysplastic syndrome
- Relapsed/refractory diffuse large B‑cell lymphoma
- Chronic lymphocytic leukemia
Studies explore novel agents, combination regimens and maintenance approaches.
Autoimmune and Inflammatory Disorders
Dedicated to therapeutic advances in systemic lupus erythematosus and related rheumatologic conditions.
- Active cutaneous lupus erythematosus
- Systemic sclerosis with interstitial lung disease
- Psoriatic arthritis
- Granulomatosis with polyangiitis
Research includes biologic modulation and organ‑specific outcome measures.
Cardiovascular and Metabolic Disease
Explores interventions for atherosclerotic cardiovascular disease and metabolic dysfunction.
- Elevated lipoprotein(a) management
- Heart failure with preserved ejection fraction
- Obesity‑related insulin resistance
- Hypertrophic cardiomyopathy in genetic carriers
Efforts target risk reduction, biomarker‑guided therapy and patient‑centered outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.